NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Anixa Biosciences, Inc. (ANIX) Stock Analysis

Anixa Biosciences, Inc. (ANIX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ANIX

$2.71

+$0.03 (+1.12%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ANIX with… →

ANIX Key Statistics

As of Oct 21, 2026
Trading
Open
$2.68
Previous Close
$2.68
Day's Range
2.66–2.75
52-Week Range
2.32–5.46
Volume
115.73K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.48
Valuation
Market Cap
$94.21M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
−0.11
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.32
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$10.93M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
34.76M
1-Year Return
−35.17%
Dividend and dates
Avg Volume
288.14K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ANIX closed at $2.71, −35.17% over 1 year.

Anixa Biosciences, Inc. (ANIX) has a market capitalization of $94.21M.

In fiscal 2025, ANIX reported revenue of $0.00.

ANIX Stock Return by Calendar Year

Anixa Biosciences, Inc. (ANIX) 10-year return: what $10,000 became

1 year
$10,000 $6,483
−35.17%
5 years
$10,000 $6,259
−37.41%
10 years
$10,000 $4,754
−52.46%

If you had invested $10,000 in Anixa Biosciences, Inc. (ANIX) 10 years ago, at the close on October 21, 2016, it would have been worth $4,754 at the close on October 21, 2026: −52.46% in total, −7.17% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−13.14%
2025+34.48%
2024−40.21%
2023−8.71%
2022+43.10%
2021−3.26%
2020−6.40%
2019−16.75%
2018+66.95%
2017−56.30%
2016 (partial year)+74.19%

As of October 21, 2026.

ANIX Revenue and Earnings by Fiscal Year

FY ends October
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$10.93M—
2024$0.00−$12.55M—
2023$210.00K−$9.81M−4,671.9%
2022$0.00−$13.60M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$11.70M−$10.93M—
2024$0.00$0.00−$13.83M−$12.55M—
2023$210.00K$49.00K−$11.01M−$9.81M−4,671.9%
2022$0.00$0.00−$13.88M−$13.60M—

Annual figures as reported, in the company's reporting currency. As of October 31, 2025.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Anixa Biosciences, Inc. (ANIX) at $94.21M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 4.

The 52-week range on file runs from $2.32 to $5.46. The most recent close on file for ANIX is $2.71, dated October 21, 2026. That is +$0.03 (+1.12%) against the previous close. The latest close sits 16.81% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $10.93M. Trailing earnings per share are −0.32.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads −0.11.

Over the trailing twelve months the total return is −35.17%. Measured over 10 years, that is −7.17% a year compounded. Beta against the wider market is reported at 0.48. Annualized volatility over the trailing 10 years is 92.72%.

Growth & Income

The record shows no dividend for ANIX.

So far in 2026 the total return is −13.14%. Across the complete calendar years on file, 2018 returned +66.95% and 2017 returned −56.30%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Anixa Biosciences, Inc. (ANIX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Anixa Biosciences, Inc. ANIX $94.21M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Anixa Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Anixa Biosciences, Inc.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Visit website →